Immunitybio Inc
NASDAQ:IBRX
Immunitybio Inc
NASDAQ:IBRX
Price:
8.135 USD
-11.09%
Updated:
May 6, 2024
Immunitybio Inc
Cash from Financing Activities
|
Immunitybio Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immunitybio Inc
NASDAQ:IBRX
|
Cash from Financing Activities
$558.3m
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Immunitybio Inc's Cash from Financing Activities?
Cash from Financing Activities
558.3m
USD
558.3m
USD
Based on the financial report for Dec 31, 2023, Immunitybio Inc's Cash from Financing Activities amounts to 558.3m USD.
What is Immunitybio Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
55%
55%
Over the last year, the Cash from Financing Activities growth was 139%. The average annual Cash from Financing Activities growth rates for Immunitybio Inc have been 55% over the past three years .
You don't have any saved screeners yet
